




PHARMACEUTICAL 2023

Skye Bioscience Inc.
Rank 399 of 446





PHARMACEUTICAL 2023

Skye Bioscience Inc.
Rank 399 of 446

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 8.4% points. The greatest weakness of Skye Bioscience Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -232%, being 275% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	8,944
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,119
Liabilities, Non-Current	0
Other Assets	80
Other Compr. Net Income	0
Other Expenses	6,212
Other Liabilities	0
Other Net Income	-1,163
Other Revenues	0
Property and Equipment	88
Research and Development	6,012
Selling, General and Administrative Expense	6,095

Output Variable	Value in 1000 USD
Assets	9,111
Liabilities	12,119
Expenses	18,318
Revenues	0
Stockholders Equity	-3,008
Net Income	-19,482
Comprehensive Net Income	-19,482
Economic Capital Ratio	-232%